ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 175 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2020. The put-call ratio across all filers is 0.92 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,653 | -72.8% | 411 | -64.8% | 0.00% | -80.0% |
| Q2 2023 | $53,834 | +0.9% | 1,167 | -12.3% | 0.01% | -16.7% |
| Q1 2023 | $53,333 | +24.6% | 1,330 | +43.9% | 0.01% | +20.0% |
| Q4 2022 | $42,809 | +137.8% | 924 | +111.4% | 0.01% | +150.0% |
| Q3 2022 | $18,000 | +80.0% | 437 | +155.6% | 0.00% | +100.0% |
| Q2 2022 | $10,000 | +900.0% | 171 | +677.3% | 0.00% | – |
| Q1 2022 | $1,000 | -80.0% | 22 | -62.7% | 0.00% | -100.0% |
| Q4 2021 | $5,000 | +150.0% | 59 | +136.0% | 0.00% | – |
| Q3 2021 | $2,000 | – | 25 | +733.3% | 0.00% | – |
| Q2 2021 | $0 | -100.0% | 3 | -94.7% | 0.00% | -100.0% |
| Q1 2021 | $6,000 | – | 57 | +1325.0% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 4 | -97.1% | 0.00% | -100.0% |
| Q3 2019 | $5,000 | 0.0% | 136 | +44.7% | 0.00% | -66.7% |
| Q1 2016 | $5,000 | -16.7% | 94 | +70.9% | 0.00% | -25.0% |
| Q4 2015 | $6,000 | – | 55 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |